poisar

Stocks · News reference

AbbVie Reveals Positive Data for Eczema and Weight Loss Candidates

Vandana Singh

AbbVie Inc. (NYSE:ABBV) announced clinical trial data on Wednesday for two pipeline candidates, highlighting progress in its immunology and metabolic disease portfolios. The pharma giant shared encouraging Phase 2

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

ABBV
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Benzinga Insights

    8 Of 11 Sectors Rise Friday As Growth Leads

    Friday's regular session has eight sectors higher and three lower, with growth sectors holding two of the top three positions. The leaders are clustered, with less than a quarter-point separating the top three sectors.

    ABBVAMZNAPDAVGOCOP
  3. Leo Sun

    AbbVie Stock: Buy, Sell, or Hold in October?

    AbbVie, a pharmaceutical giant with 53 consecutive years of dividend increases, remains a stable long-term investment despite losing U.S. patent exclusivity for its blockbuster drug Humira in 2023. The company has offset this decline through new immunology drugs (Skyrizi and Rinvoq) and strategic acquisitions including Allergan (Botox). Analysts project 9% revenue CAGR and 21% adjusted EPS CAGR from 2025-2028. At $264 per share with a 2.6% forward yield and 16x forward P/E, the stock is reasonably valued for buy-and-hold investors.

    ABBV